Topical pharmacokinetics of dexamethasone suspensions in the rabbit eye: Bioavailability comparison

Topical corticosteroids are used to treat inflammation of the anterior segment. Due to their low water-solubility, they are often formulated as suspensions, but ocular bioavailability of the suspensions is not known. Herein, ocular pharmacokinetics of dexamethasone in albino rabbits was investigated following intracameral administration of dexamethasone solution and topical administration of three commercial suspensions: Maxidex (R), TobraDex (R), and TobraDexST (R). Dexamethasone concentrations in tear fluid, cornea, aqueous humor, conjunctiva and iris-ciliary body were determined. Non-compartmental analysis was performed to estimate the pharmacokinetic parameters of dexamethasone. Following intracameral administration, the clearance and the apparent volume of distribution were estimated to be 13.6 mu L/min and 990 mu L, respectively. After topical administration, the absolute aqueous humor bioavailability for dexamethasone (<2%) is being reported for the first time. The highest value was obtained for TobraDexST (R) followed by Maxidex (R) and TobraDex (R). This study provides for the first-time comprehensive and quantitative ocular pharmacokinetic parameters (including absolute bioavailability) for topically instilled dexamethasone suspensions. Furthermore, the new intracameral pharmacokinetic parameters allow a rational and quantitative basis for the design of improved ocular dexamethasone delivery systems.